In June 2024, Haier Biomedical Co., Ltd. (“Haier Biomedical”) announced the cancellation of 1,459,600 previously repurchased A-shares. This move marks a key step in fulfilling the company’s share repurchase program, aimed at optimizing its capital structure, enhancing earnings per share (EPS), and signaling strong confidence in its long-term value.According to the announcement, Haier Biomedical had repurchased these shares via centralized bidding transactions for approximately RMB 50 million, based on its positive outlook on future growth and intrinsic value assessment. Following the cancellation, the company’s total share capital will decrease accordingly, which is expected to improve return on equity (ROE) and EPS, thereby strengthening shareholder returns.Share repurchase followed by cancellation is a common market-value management strategy among listed companies. It reduces the number of outstanding shares and reflects management’s confidence in the company’s fundamentals and growth prospects—often interpreted by investors as a positive signal that may support share price stability or appreciation.As a global leader in biosafety solutions, Haier Biomedical continues to drive innovation in life sciences and public health. This share cancellation further underscores its solid financial position and shareholder-centric business philosophy.
2024年6月，海尔生物医疗股份有限公司（简称“海尔生物”）发布公告，宣布将注销此前回购的145.96万股A股股份。此次注销是公司履行其股份回购计划的重要一步，旨在优化公司股本结构、提升每股收益，并向市场传递对公司长期价值的信心。根据公告，海尔生物此前基于对公司未来发展前景的认可和对自身价值的判断，通过集中竞价交易方式回购了这部分股份，总金额约为人民币5,000万元。本次注销完成后，公司总股本将相应减少，有助于提高净资产收益率（ROE）和每股盈利水平，从而增强股东回报。值得注意的是，股份回购并注销是上市公司常用的市值管理手段之一。此举不仅减少了流通股数量，还体现了管理层对公司基本面和未来成长性的坚定信心。对于投资者而言，这通常被视为积极信号，可能对股价形成支撑。海尔生物作为全球领先的生物安全解决方案提供商，在生命科学、公共卫生等领域持续创新。此次股份注销行动进一步彰显其稳健的财务状况与以股东利益为导向的经营理念。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/8986.html